Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Target organic growth: 12% to 15% per year going forward, improving from 8% in FY25. The company aspires to achieve a 15% revenue growth rate internally.
From Jagsonpal Pharmaceuticals Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Target organic growth: 12% to 15% per year going forward, improving from 8% in FY25.
- Inorganic growth not forecasted due to unpredictability of acquisitions.
- Growth driven by improved medical rep productivity (currently INR2 to 2.1 lakhs PCPM) with aspiration to increase productivity by 50% over 3-4 years.
- Sales growth impacted by product mix changes; volumes have been flat due to decline in specific franchises like Dydrogesterone.
- Launching 4 to 6 new products annually, mainly extensions and some new molecules.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Jagsonpal Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Jagsonpal Pharmaceuticals follows an asset-light model with no own manufacturing; all products for India are produced using CMOs.
- The company has no significant capex plans for building plants or machinery.
- Investment is primarily in computer infrastructure and office/field force technology.
- Real capital investment focus is on acquisitions – primarily brand or business acquisitions fitting strategic therapeutic areas.
- The company remains disciplined on acquisitions, focusing on fair valuations and value addition for shareholders.
- If suitable acquisition targets are not found, surplus cash will be returned to shareholders instead of spending on overpriced or non-strategic deals.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jagsonpal Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Jagsonpal Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹64 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jagsonpal Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmova Ltd (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare Ltd (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals Ltd (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Frequently Asked Questions
What were Jagsonpal Pharmaceuticals Ltd Q4 FY25 results?
Target organic growth: 12% to 15% per year going forward, improving from 8% in FY25. The company aspires to achieve a 15% revenue growth rate internally.
What is Jagsonpal Pharmaceuticals Ltd share price analysis?
Jagsonpal Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 31.8 with a market cap of ₹1,494 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jagsonpal Pharmaceuticals Ltd planning capital expenditure?
Jagsonpal Pharmaceuticals follows an asset-light model with no own manufacturing; all products for India are produced using CMOs.
Keep Jagsonpal Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.